ライフサイエンスコーパス: inflammatory bowel disease

1 ocalized gut inflammatory conditions such as inflammatory bowel disease.

2 sociated colon cancer (CAC) in patients with inflammatory bowel disease.

3 ted with immune-mediated diseases, including inflammatory bowel disease.

4 ns that contribute to events associated with inflammatory bowel disease.

5 ay a role in disease status in patients with inflammatory bowel disease.

6 its impairment leads to pathogenesis such as inflammatory bowel disease.

7 ing shared pathobiology between COVID-19 and inflammatory bowel disease.

8 in a replication cohort of 178 patients with inflammatory bowel disease.

9 to excessive immune responses as observed in inflammatory bowel disease.

10 as well as diseases such as bowel cancer and inflammatory bowel disease.

11 ads to dysplasia and cancer in patients with inflammatory bowel disease.

12 issue in a murine colitis model and in human inflammatory bowel disease.

13 spects of the dysbiosis that occurs in human inflammatory bowel disease.

14 revealing the closest genetic relatedness to inflammatory bowel disease.

15 dd to the burden of illness in patients with Inflammatory Bowel Disease.

16 easures assessing self-care in patients with inflammatory bowel disease.

17 ve body composition changes in patients with Inflammatory Bowel Disease.

18 Rag/CD25(-) CD4(+) T cell transfer model of inflammatory bowel disease.

19 assessment of self-care among patients with inflammatory bowel disease.

20 t has been implicated in the pathogenesis of inflammatory bowel disease.

21 y diseases, such as rheumatoid arthritis and inflammatory bowel disease.

22 between microbially produced metabolites and inflammatory bowel disease.

23 g the quality of surveillance colonoscopy in inflammatory bowel disease.

24 ions including type 2 diabetes, obesity, and inflammatory bowel disease.

25 ed as a noteworthy pathogen in patients with inflammatory bowel disease.

26 colonic epithelium from luminal threats and inflammatory bowel disease.

27 from developing immunological diseases like inflammatory bowel disease.

28 ncreased risk of acute pancreatitis in adult inflammatory bowel disease.

29 sites of bacteria-associated inflammation in inflammatory bowel disease.

30 the context of microbiotas from humans with inflammatory bowel disease.

31 report with a morphology code suggestive of inflammatory bowel disease.

32 ultrasound in the detection and follow-up of inflammatory bowel disease.

33 Galectin-9 is a risk gene in inflammatory bowel disease.

34 sm through which diet modulates the onset of inflammatory bowel disease.

35 tial targets for therapeutic intervention in inflammatory bowel disease.

36 ing has been linked to pathologies including inflammatory bowel disease.

37 he cases of KS in HIV-negative patients with inflammatory bowel disease.

38 e the importance of childbearing for risk of inflammatory bowel disease.

39 f numerous inflammatory conditions including inflammatory bowel disease.

40 le in the initial diagnosis and follow-up of inflammatory bowel disease.

41 as been identified as a gut damage marker in inflammatory bowel diseases.

42 sceral hypersensitivity (VH) with underlying inflammatory bowel diseases.

43 abis have been investigated in patients with inflammatory bowel diseases.

44 s expression and phosphorylation patterns in inflammatory bowel diseases.

45 valence of noncommunicable disorders such as inflammatory bowel diseases.

46 ment of chronic inflammation, as observed in inflammatory bowel diseases.

47 inflammatory responses, most notably during inflammatory bowel diseases.

48 Tr1 cells might be used in the treatment of inflammatory bowel diseases.

49 tment of immune-mediated diseases, including inflammatory bowel diseases.

50 seases, such as cancer, cystic fibrosis, and inflammatory bowel diseases.

51 identify patients at risk for development of inflammatory bowel diseases.

52 used to study apoptotic enterocolopathy and inflammatory bowel diseases.

53 both small-bowel diagnosis and monitoring in inflammatory bowel diseases.

54 ing pathways, which have also been linked to inflammatory bowel diseases.

55 on cohort to as high as 78% in patients with inflammatory bowel disease(2).

56 54), chronic kidney disease, 3.9% (n=18) and inflammatory bowel disease, 21.9% (n=101).

57 zed (median age 43 years, 58% male, 60% with inflammatory bowel disease, 46% on ursodeoxycholic acid)

58 illion), abdominal pain ($10.2 billion), and inflammatory bowel disease ($7.2 billion) were the most

59 roctocolitis (23.2%) and family history with inflammatory bowel diseases (9.4%) and celiac disease (7

60 ntial therapeutic strategy for patients with inflammatory bowel disease(9).

61 ction(5-7), graft-versus-host disease(8) and inflammatory bowel disease(9,10).

62 Case reports suggest an association between inflammatory bowel disease, a chronic autoimmune conditi

63 bacterial metabolic pathways associated with inflammatory bowel disease across two completely indepen

64 ional dysbiosis in the gut microbiome during inflammatory bowel disease activity.

65 y and 330 (1.65%) matched controls developed inflammatory bowel disease (adjusted HR, 3.29; 95% confi

66 We also explored whether inflammatory bowel disease affects development of ESKD i

67 he dominating isotype, whereas patients with inflammatory bowel disease also produce high concentrati

68 Inflammatory bowel disease also was more common before a

69 as arthritis, multiple sclerosis, psoriasis, inflammatory bowel disease, among others) and in the hos

70 The presence of a concomitant inflammatory bowel disease, an autoimmune hepatitis or i

71 f FERM was further demonstrated in models of inflammatory bowel disease and 4T1 tumor.

72 in physically unfit patients with quiescent Inflammatory Bowel Disease and can quickly achieve favou

73 A role of sphingolipids for inflammatory bowel disease and cancer is evident.

74 hat have been implicated in diseases such as inflammatory bowel disease and cancer.

75 c regions containing susceptibility loci for inflammatory bowel disease and chronic pancreatitis are

76 significant risk factor for pCCA followed by inflammatory bowel disease and cirrhosis, whereas other

77 Inflammatory bowel disease and colorectal cancer data se

78 ated with up-regulation of DUOX2 and NOX1 in inflammatory bowel disease and colorectal cancer.

79 IL-33, a cytokine upregulated in inflammatory bowel disease and helminth infection, induc

80 lays a vital role in conditions ranging from inflammatory bowel disease and HIV through to sepsis and

81 atients and stool of pediatric patients with inflammatory bowel disease and in tissue sections of pat

82 ) have been found to differ in patients with inflammatory bowel disease and irritable bowel syndrome.

83 g used to treat multiple forms of arthritis, inflammatory bowel disease and myeloproliferative neopla

84 ther immune-mediated diseases, most commonly inflammatory bowel disease and rheumatoid arthritis.

85 rosing cholangitis, which is associated with inflammatory bowel disease and with an increased inciden

86 (JAKs) are being developed for treatment of inflammatory bowel diseases and other immune-mediated di

87 e risk of CRN and colectomy in patients with inflammatory bowel diseases and PIPs.

88 logical and genetical evidence linking PD to inflammatory bowel diseases and we recently demonstrated

89 mune diseases, including multiple sclerosis, inflammatory bowel disease, and allergic disease.

90 icularly, ulcerative colitis, Crohn disease, inflammatory bowel disease, and chronic pancreatitis are

91 gions for ulcerative colitis, Crohn disease, inflammatory bowel disease, and chronic pancreatitis wer

92 iseases, including irritable bowel syndrome, inflammatory bowel disease, and colorectal cancer.

93 igh risk for breast cancer, type 2 diabetes, inflammatory bowel disease, and coronary heart disease,

94 , including systemic lupus erythematosus and inflammatory bowel disease, and our previous work sugges

95 junction protein claudin-2 is upregulated in inflammatory bowel disease, and yet its deficit worsens

96 with NLRs impact the modulation of colitis, inflammatory bowel diseases, and colorectal cancer.

97 in many patients as malabsorption syndrome, inflammatory bowel disease, anorexia nervosa, and intest

98 Inflammatory bowel diseases are associated with complex

99 Inflammatory bowel diseases are classic polygenic disord

100 Intestinal inflammatory disorders, such as inflammatory bowel disease, are major contributors to mo

101 erformance and, notably, to some humans with inflammatory bowel disease as a therapeutic agent that m

102 ysis identified age and diagnoses other than inflammatory bowel disease as significant risk factors f

103 ide crucial insight into the pathogenesis of inflammatory bowel disease as well as new avenues to pre

104 eriodontal disease, rheumatoid arthritis and inflammatory bowel diseases, as well as a synthetic benc

105 ble spontaneous autoimmune diseases, such as inflammatory bowel disease, autoimmune thyroid disease,

106 s performed for neoplastic, diverticular, or inflammatory bowel disease between 2008 and 2015.

107 th IgA nephropathy have an increased risk of inflammatory bowel disease both before and after their n

108 inflammatory diseases, such as psoriasis and inflammatory bowel disease, but not in asthmatic patient

109 have been investigated in the development of inflammatory bowel diseases, cancer, metabolic syndrome,

110 linical trials have revealed clusters of new inflammatory bowel disease cases amongst psoriasis patie

111 nts for ulcerative colitis, Crohn's disease, inflammatory bowel disease, celiac disease, chronic panc

112 Exclusion criteria were studies of inflammatory bowel disease cohorts, referrals for diffic

113 ulcerative colitis, and 26 patients without inflammatory bowel diseases (control individuals).

114 from 8 adults and 10 newborn infants without inflammatory bowel diseases (controls) and 8 infants wit

115 Assessment of self-care in patients with inflammatory bowel disease could allow targeted support

116 ciated with increased risk of developing the inflammatory bowel disease Crohn's disease, thus suggest

117 at plays a vital role in the pathogenesis of inflammatory bowel diseases-Crohn disease and ulcerative

118 Inflammatory bowel disease data and ESKD status were obt

119 53%) IgA nephropathy patients had an earlier inflammatory bowel disease diagnosis compared with 220 (

120 ns regarding the management of patients with inflammatory bowel disease during the coronavirus diseas

121 mong patients with IgA nephropathy, comorbid inflammatory bowel disease elevates the risk of progress

122 a critical role in combatting the effects of inflammatory bowel disease, fistulae and ulcers.

123 Inflammatory bowel diseases frequently cause gastrointes

124 s, an Internet-based cohort of patients with inflammatory bowel disease, from November 2013 through J

125 The relationship between PSC and inflammatory bowel disease has inspired theories that in

126 is growing evidence to suggest patients with inflammatory bowel disease have an increased risk of pos

127 Patients with inflammatory bowel disease have been shown to have abnor

128 carrying susceptibility genes implicated in inflammatory bowel disease (IBD) (Nod2 and Atg16l1) upon

129 n categorizing samples from individuals with inflammatory bowel disease (IBD) and healthy controls.

130 edominantly African American population with inflammatory bowel disease (IBD) and Non-IBD/Non-Infecti

131 is process occur frequently in patients with inflammatory bowel disease (IBD) and other mucosal disor

132 and piroxicam-accelerated Il10-/- models of inflammatory bowel disease (IBD) and reduced elevated le

133 A), as exemplified by the high prevalence of inflammatory bowel disease (IBD) and the even higher occ

134 ived GSDMD is observed both in patients with inflammatory bowel disease (IBD) and those with experime

135 Patients with inflammatory bowel disease (IBD) are at increased risk o

136 Plaque psoriasis and inflammatory bowel disease (IBD) are both chronic immune

137 hole-virome analysis on a published keystone inflammatory bowel disease (IBD) cohort and an in-house

138 ,379 metagenomes from four human cohorts: an inflammatory bowel disease (IBD) cohort, an obese cohort

139 sease (CD), ulcerative colitis (UC), and non-inflammatory bowel disease (IBD) controls.

140 The increased incidence of inflammatory bowel disease (IBD) has become a global phe

141 I adverse events in patients with cancer and inflammatory bowel disease (IBD) has not been well descr

142 Patients with inflammatory bowel disease (IBD) have an increased risk

143 Studies of inflammatory bowel disease (IBD) have been inconclusive

144 Pediatric-onset colitis and inflammatory bowel disease (IBD) have significant effect

145 pectra of irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) intersect to form a sca

146 Inflammatory bowel disease (IBD) is a chronic complex di

147 Inflammatory bowel disease (IBD) is a chronic disorder c

148 Inflammatory bowel disease (IBD) is a chronic immune-med

149 Inflammatory bowel disease (IBD) is a chronic inflammato

150 Inflammatory bowel disease (IBD) is a chronic inflammato

151 Inflammatory bowel disease (IBD) is a common chronic inf

152 Inflammatory bowel disease (IBD) is a complex genetic di

153 Inflammatory bowel disease (IBD) is a complex multi-fact

154 Inflammatory bowel disease (IBD) is a debilitating chron

155 Inflammatory bowel disease (IBD) is an expanding autoimm

156 Inflammatory bowel disease (IBD) is associated with the

157 Childhood-onset inflammatory bowel disease (IBD) is believed to be a mor

158 for ileocolonoscopy for clinically suspected inflammatory bowel disease (IBD) is not well defined, an

159 Chronic pediatric inflammatory bowel disease (IBD) leads to lack of bone a

160 Pregnant women with inflammatory bowel disease (IBD) may require biologic or

161 ge polarization and dysbiosis contributes to inflammatory bowel disease (IBD) pathogenesis.

162 berrant lysozyme production are hallmarks of inflammatory bowel disease (IBD) pathology.

163 nd neutrophil activity are closely linked to inflammatory bowel disease (IBD) pathophysiology.

164 The detection of Clostridioides difficile in inflammatory bowel disease (IBD) patients is a common oc

165 tive surgery and corresponding mortality for inflammatory bowel disease (IBD) patients since the rise

166 nt extra-intestinal manifestations (EIMs) in inflammatory bowel disease (IBD) patients, and they are

167 ia STAT3 activation promotes inflammation in inflammatory bowel disease (IBD) patients.

168 Patients with inflammatory bowel disease (IBD) present with reduced se

169 However, the function of Arg1 in inflammatory bowel disease (IBD) remains poorly characte

170 The in vitro study of the pathogenesis of inflammatory bowel disease (IBD) requires a cell model w

171 on the best way to integrate biomarkers into inflammatory bowel disease (IBD) research and clinical p

172 isk scores (PRS) may soon be used to predict inflammatory bowel disease (IBD) risk in prevention effo

173 Patients with inflammatory bowel disease (IBD) tend to avoid dairy pro

174 estinal fibrosis is a common complication of inflammatory bowel disease (IBD) that is usually the con

175 Crohn's disease (CD) is a chronic relapsing inflammatory bowel disease (IBD) that may be marked by d

176 Hospitalisation rates for inflammatory bowel disease (IBD) vary across the world.

177 ns have been associated with the severity of inflammatory bowel disease (IBD)(2,5), the diverse immun

178 ctal cancer (CRC), colonic lesions caused by inflammatory bowel disease (IBD), and normal thickened c

179 influence the development and progression of inflammatory bowel disease (IBD), but determining genera

180 recommended for iron-deficient patients with inflammatory bowel disease (IBD), but may be associated

181 resistance is a major clinical challenge in inflammatory bowel disease (IBD), due, in part, to insuf

182 rget in diseases of the intestine, including inflammatory bowel disease (IBD), graft-versus-host dise

183 une dysregulation resulting in autoimmunity, inflammatory bowel disease (IBD), hypogammaglobulinemia,

184 ession levels are increased in patients with inflammatory bowel disease (IBD), including Crohn's dise

185 Inflammatory bowel disease (IBD), including Crohn's dise

186 ctal cancer (CRC), advanced adenoma (AA), or inflammatory bowel disease (IBD), is uncommon.

187 in multiple, large cohorts of patients with inflammatory bowel disease (IBD), we have studied the in

188 Complex diseases such as inflammatory bowel disease (IBD), which consists of ulce

189 purine which has been used for patients with inflammatory bowel disease (IBD), who have failed azathi

190 is a common extraintestinal manifestation in inflammatory bowel disease (IBD), yet, the mechanisms dr

191 ignificantly down-regulated in patients with inflammatory bowel disease (IBD).

192 (FODMAPs) reduces gut symptoms in quiescent inflammatory bowel disease (IBD).

193 multiple immune-mediated diseases, including inflammatory bowel disease (IBD).

194 ith several inflammatory diseases, including inflammatory bowel disease (IBD).

195 ys a significant role in the pathogenesis of inflammatory bowel disease (IBD).

196 colitis shares pathogenetic mechanisms with inflammatory bowel disease (IBD).

197 ed infants with diagnosed celiac disease and inflammatory bowel disease (IBD).

198 posure on male reproduction in patients with Inflammatory Bowel Disease (IBD).

199 the intestinal microbiome are implicated in inflammatory bowel disease (IBD).

200 increased risk of serious infection in adult inflammatory bowel disease (IBD).

201 IgA nephropathy, ankylosing spondylitis, and inflammatory bowel disease (IBD).

202 inistration as a possible oral treatment for inflammatory bowel disease (IBD).

203 8 inhibition as immunomodulatory therapy for inflammatory bowel disease (IBD).

204 (DSG2) is a hallmark in the pathogenesis of inflammatory bowel disease (IBD).

205 10 signaling in macrophages (Mphis) leads to inflammatory bowel disease (IBD).

206 reakdown of the epithelial barrier underpins inflammatory bowel disease (IBD).

207 initial presenting symptoms of patients with inflammatory bowel disease (IBD).

208 clerosing cholangitis (PSC) in patients with inflammatory bowel disease (IBD).

209 ith healthy controls (HCs) and patients with inflammatory bowel disease (IBD).

210 inal tract contributes to the development of inflammatory bowel disease (IBD).

211 dentified as a novel susceptibility gene for inflammatory bowel disease (IBD).

212 Inflammatory Bowel Diseases (IBD) affect psychological,

213 Inflammatory bowel diseases (IBD) are associated with al

214 Children with inflammatory bowel diseases (IBD) are particularly vulne

215 y of CD patients seen at a tertiary academic inflammatory bowel diseases (IBD) clinic was compared to

216 Inflammatory bowel diseases (IBD) develop via convergenc

217 e number of therapeutic options for treating inflammatory bowel diseases (IBD) is increasing, evidenc

218 Inflammatory bowel diseases (IBD), that includes ulcerat

219 relate with clinical outcomes of adults with inflammatory bowel diseases (IBD).

220 association between celiac disease (CeD) and inflammatory bowel diseases (IBD).

221 betes, nonalcoholic fatty liver disease, and inflammatory bowel diseases (IBD).

222 nal microbiota contribute to pathogenesis of inflammatory bowel diseases (IBD).

223 onic intestinal inflammation, as observed in inflammatory bowel diseases (IBD).

224 ocyte-derived macrophages from patients with inflammatory bowel disease [IBD]) or mouse macrophages,

225 ms of mucosal dysregulation in patients with inflammatory bowel diseases (IBDs) and differences in in

226 Inflammatory bowel diseases (IBDs) exist worldwide, with

227 Patients with inflammatory bowel diseases (IBDs) have intestinal barri

228 roportion of infants and young children with inflammatory bowel diseases (IBDs) have subtypes associa

229 f European ancestry, the epidemiology of the inflammatory bowel diseases (IBDs) is changing.

230 Inflammatory bowel diseases (IBDs) such as Crohn's disea

231 cerative colitis are chronic and progressive inflammatory bowel diseases (IBDs) that are attributed t

232 robiota has been proposed as a treatment for inflammatory bowel diseases (IBDs), but there are no est

233 For instance, in course of inflammatory bowel diseases (IBDs), in particular Crohn'

234 Inflammatory bowel diseases (IBDs), including Crohn's di

235 in mucosal inflammation and diseases such as inflammatory bowel diseases (IBDs), is often associated

236 This is particularly evident in inflammatory bowel diseases (IBDs), where clinical trial

237 The inflammatory bowel diseases (IBDs), which include Crohn'

238 17 years for RA; and 36.9 and 3.69 years for inflammatory bowel diseases (IBDs).

239 effect of immunosuppression for treatment of inflammatory bowel diseases (IBDs).

240 eep apnea, cardiopathy, renal insufficiency, inflammatory bowel disease, immunosuppression, anticoagu

241 el syndrome were made in 2 patients (1%) and inflammatory bowel disease in 2 patients (1%).

242 Mutations in FAMIN cause arthritis and inflammatory bowel disease in early childhood, and a com

243 hil dysfunction cause serious infections and inflammatory bowel disease in glycogen storage disease t

244 n to estimate hazard ratios (HRs) for future inflammatory bowel disease in IgA nephropathy and condit

245 ogistic regression to assess risk of earlier inflammatory bowel disease in IgA nephropathy.

246 Recent studies traced inflammatory bowel disease in some patients to deficienc

247 pecific subsets of commensal bacteria induce inflammatory bowel diseases in genetically susceptible h

248 d may function as a susceptibility factor in inflammatory bowel diseases in humans.

249 ive arthritis, the arthritis associated with inflammatory bowel disease including Crohn's disease and

250 anding immunosuppressive therapy, such as in inflammatory bowel disease including ulcerative colitis

251 ition and function have been associated with inflammatory bowel diseases, including ulcerative coliti

252 copy who had received infliximab therapy for inflammatory bowel diseases; infliximab-TNF complexes we

253 Inflammatory bowel disease is a chronic, relapsing condi

254 erves a pathogenic or protective role during inflammatory bowel disease is controversial.

255 helial homeostasis and in the development of inflammatory bowel diseases is not fully understood.

256 or limitation of these data for the study of inflammatory bowel diseases is the absence of detailed c

257 C1, previously C13orf31) are associated with inflammatory bowel disease, leprosy, Behcet disease, and

258 of variants influencing type 2 diabetes and inflammatory bowel disease, making them good candidates

259 eticulum stress, insults commonly present in inflammatory bowel diseases, mediated the cyclic switch

260 clinicians because organic causes, including inflammatory bowel disease, microscopic colitis, and chr

261 mouse dextran sodium sulfate-induced chronic inflammatory bowel disease model, with efficacy similar

262 cytokine 1A (TL1A, TNFSF15) is implicated in inflammatory bowel disease, modulating the location and

263 and/or polymyalgia rheumatica (n = 25,581), inflammatory bowel disease (n = 27,739), rheumatoid arth

264 nding its role in various diseases including inflammatory bowel disease, neurologic diseases, cardiov

265 In particular, inflammatory bowel diseases, obesity, diabetes, asthma a

266 Ulcerative colitis (UC) is a chronic inflammatory bowel disease of unknown aetiology affectin

267 are present, or there is a family history of inflammatory bowel disease or coeliac disease.

268 t affect the gastrointestinal tract, such as inflammatory bowel disease or Cystic Fibrosis.

269 n humans, and were enriched in patients with inflammatory bowel disease or cystic fibrosis.

270 Those with uncontrolled inflammation due to inflammatory bowel disease or eosinophilic gastrointesti

271 UC in elderly-onset patients followed at our Inflammatory Bowel Disease outpatient clinic and compare

272 clude heart failure, chronic kidney disease, inflammatory bowel disease, patient blood management in

273 ic analyses of ileal biopsies and PBMCs from inflammatory bowel disease patients, we identified a pos

274 limited to open procedures for neoplasia and inflammatory bowel disease patients.

275 a cohort of healthy individuals at risk for inflammatory bowel diseases (pre-UC) who later developed

276 , 43% were in high-risk patients (those with inflammatory bowel disease, previous CRC, previous multi

277 tis, diabetes, systemic lupus erythematosus, inflammatory bowel disease, psoriasis, Sjogren syndrome,

278 tinib in patients with rheumatoid arthritis, inflammatory bowel diseases, psoriasis, or ankylosing sp

279 Dimensions [EQ-5D], Short Quality of Life in Inflammatory Bowel Disease Questionnaire [SIBDQ], and Wo

280 s for ulcerative colitis, Crohn disease, and inflammatory bowel disease remained associated with PDAC

281 of frequent infections, mucosal lesions, and inflammatory bowel disease resolved, and no symptomatic

282 tween six immune diseases and schizophrenia: inflammatory bowel disease (rg = 0.12 +/- 0.03, P = 2.49

283 ignificantly correlated with reduction of an inflammatory bowel disease risk gene ATG16L1 and Paneth

284 tially increase the likelihood of finding an inflammatory bowel disease-specific fecal VOC marker pro

285 Kingdom) data from the 2015 and 2017 Adelphi Inflammatory Bowel Disease-Specific Programme (IBD-DSP)

286 the causal effect of elevated IL18 levels on inflammatory bowel disease susceptibility (IBD) in 12,88

287 Crohn's disease is an inflammatory bowel disease that is characterized by chro

288 reg, and examines how targeting RORgammat in inflammatory bowel disease therapy could influence the d

289 In patients with inflammatory bowel disease, there is a breakdown of the

290 dence related to surveillance colonoscopy in inflammatory bowel disease to look at the different vari

291 tool to assess the ability of patients with inflammatory bowel disease to perform routine self-care.

292 ty, whereas in an adoptive transfer model of inflammatory bowel disease, transfer of p73-deficient na

293 Very-early-onset inflammatory bowel disease (VEO-IBD) is a heterogeneous

294 Very early onset inflammatory bowel disease (VEOIBD) denotes children wit

295 .84; 95% CI, 1.33 to 2.55) demonstrated that inflammatory bowel disease was associated with increased

296 No deaths or cases of inflammatory bowel disease were reported.

297 Patients with inflammatory bowel diseases who have postinflammatory po

298 are the two forms of disorders of the human inflammatory bowel disease with unknown etiologies.

299 , a mucosal galectin that has been linked to inflammatory bowel disease, within the context of the mu

300 mune disorders like rheumatoid arthritis and inflammatory bowel disease yet increases susceptibility